Latham & Watkins Advises Perceptive Advisors on Growth Financing for Leading Oncology Biotech Autolus Therapeutics

Autolus Therapeutics plc (Nasdaq: AUTL) announced that it has entered into a senior secured notes facility of up to US$250 million with Perceptive Advisors, consisting of an initial issuance of US$75 million, an additional US$25 million available at Autolus’ option, and up to US$150 million of additional notes available upon the achievement of specified revenue milestones. In connection with the financing, Autolus also issued Perceptive a warrant to purchase up to 3.5 million American Depositary Shares. The company expects the notes issuance, together with existing cash resources, to provide funding into the second quarter of 2028.

Latham & Watkins LLP advised Perceptive Advisors in the transaction with a finance team led by partners Haim Zaltzman and Liz Oh, and counsel Ben Gelfand.* Advice was also provided on UK finance matters by partner Paul Yin; on US corporate matters by partner Drew Capurro; on UK corporate matters by partner Shing Lo and counsel Koushik Prasad; on US tax matters by partner Eric Cho; on UK tax matters by partner Aoife McCabe; on UK real estate matters by partner Quentin Gwyer; on US healthcare regulatory matters by partners Betty Pang and Elizabeth Richards, and counsel Chad Jennings; on UK healthcare regulatory matters by partner Eveline Van Keymeulen; on US intellectual property matters by counsel Rob Yeh; on US security matters by counsel Emily Yu; on US ERISA matters by partner Julie Crisp; on UK pension matters by counsel Shaun Thompson; on data privacy and cybersecurity matters by partner Heather Deixler; and on German law matters by partner Sibylle Muench.